Program
dapagliflozin
Also written as “Dapagliflozin”, “Dapagliflozin 10 mg” and “Dapagliflozin 10mg”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Renal Insufficiency, Chronic · Heart Failure · Diabetes Mellitus · Diabetes Mellitus, Type 1, led by 14 companies.
Drug pageDapagliflozin: every studyMany companies study it; this page follows only the 131 they lead. All 485 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 10910 open or running | phase 4since Jun 2, 2014 | Sep 9, 2005 | Dec 10, 2026phase 2 · NCT07222917 |
| LG Chemits history only | 60 open or running | phase 3since Feb 2, 2020 | May 24, 2018 | none ahead |
| Boryung Pharmaceuticalits history only | 32 open or running | phase 1since May 26, 2022 | May 26, 2022 | none ahead |
| Dong-A STits history only | 20 open or running | phase 3since Apr 20, 2020 | Dec 5, 2018 | none ahead |
| Hansoh Pharmaceutical Groupits history only | 20 open or running | phase 1since Apr 30, 2021 | Apr 30, 2021 | none ahead |
| autotelicbioits history only | 10 open or running | phase 1since Apr 20, 2021 | Apr 20, 2021 | none ahead |
| Daewoong Pharmaceuticalits history only | 10 open or running | phase 3since Nov 12, 2020 | Nov 12, 2020 | none ahead |
| Dexa Medica Groupits history only | 10 open or running | no phasesince Nov 7, 2023 | Nov 7, 2023 | none ahead |
| dong-wha-pharmaceutical-co-ltdits history only | 10 open or running | phase 1since May 4, 2022 | May 4, 2022 | none ahead |
| George Clinical Ptyits history only | 10 open or running | phase 4since Nov 3, 2020 | Nov 3, 2020 | none ahead |
| Hamad Medicalits history only | 10 open or running | phase 3since Jul 22, 2018 | Jul 22, 2018 | none ahead |
| Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chairits history only | 11 open or running | phase 3since Jun 16, 2025 | Jun 16, 2025 | none ahead |
| Novartisits history only | 10 open or running | phase 2since May 21, 2021 | May 21, 2021 | none ahead |
| thpharm-corpits history only | 10 open or running | phase 1since Sep 8, 2023 | Sep 8, 2023 | none ahead |
- Named in AstraZeneca’s own pipeline as
zibotentan/dapagliflozin
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: Fortrea, Parexel, Ground Zero Pharmaceuticals, PT Equilab International, Bristol-Myers Squibb, Q2 Solutions, PRA Health Sciences, Covance and Antaros Medical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 44 studies since Mar 15, 2016.
- Nov 5, 2024Phase 3 study in Heart FailureAstraZeneca · NCT06677060 · 11,300 planned · United States, Argentina, Australia and more
- Dec 16, 2024Phase 3 study in Renal Insufficiency, ChronicAstraZeneca · NCT06742723 · 5,000 planned · United States, Argentina, Australia and more
- Apr 17, 2025Phase 2 study in Kidney DiseasesAstraZeneca · NCT06942910 · 224 enrolled · Russia
- May 5, 2025Phase 1 study in Lecithin Cholesterol Acyltransferase DeficiencyAstraZeneca · NCT06979388 · 14 enrolled · United Kingdom
- Jun 16, 2025Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair’s first study: phase 3 study in Diabetes Mellitus, Type 2New to Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB ChairHan Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair · NCT07033585 · 600 enrolled · United States
- Jul 16, 20252 phase 1 studies in Diabetes MellitusBoryung Pharmaceutical · NCT07083401, NCT07083388
- Oct 17, 2025Phase 2 study in Renal Insufficiency, ChronicAstraZeneca · NCT07222917 · 222 enrolled · United States, Argentina, Bulgaria and more
- Nov 24, 2025Phase 1 study in Fed ConditionsLG Chem · NCT07333742 · 50 enrolled · South Korea
- Jan 23, 2026Phase 1 study in Healthy VolunteersLG Chem · NCT07399470 · 58 enrolled · South Korea
- Feb 2, 2026Phase 1 study in FastingLG Chem · NCT07396844 · 28 enrolled · Thailand
- Feb 5, 2026Phase 1 study in Renal Insufficiency, ChronicAstraZeneca · NCT07404137 · 26 enrolled · United States
- May 29, 2026Phase 3 study in Renal Insufficiency, ChronicAstraZeneca · NCT07624305 · 2,800 planned · United States, Argentina, Austria and more
- Jun 18, 20262 phase 3 studies in Diabetes Mellitus, Type 2AstraZeneca · NCT07662109, NCT07662044
- Jul 13, 2026Phase 1 study in Renal InsufficiencyAstraZeneca · NCT07754331 · 10 enrolled · United States
Ahead
- Dec 10, 2026Primary completion: phase 2 study in Renal Insufficiency, ChronicAstraZeneca · NCT07222917
- Feb 18, 2027Primary completion: phase 3 study in Kidney DiseasesAstraZeneca · NCT06087835
- May 31, 2027Primary completion: phase 4 study in Renal Insufficiency, ChronicAstraZeneca · NCT06610526
- Feb 24, 2028Primary completion: phase 3 study in Renal Insufficiency, ChronicAstraZeneca · NCT06268873
TargetBeta
“The propanediol form of dapagliflozin, a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Upon administration, dapagliflozin selectively targets and inhibits SGLT2, thereby preventing the reabsorption of glucose by the kidneys.”NCIt, read by Claude
“The propanediol form of dapagliflozin, a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity”NCIt, by rule
“Sodium/glucose cotransporter 2 inhibitor; Sodium/glucose cotransporter 2 inhibitor”ChEMBL 37, by rule
Other programs on SLC5A2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| empagliflozinrule | Boehringer Ingelheim | phase 4 | 142 |
| ertugliflozinrule | Merck | phase 4 | 22 |
| Enavogliflozinrule | Daewoong Pharmaceutical | phase 3 | 25 |
| vicadrostat | Boehringer Ingelheim | phase 3 | 16 |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 2 |
Studies
The newest 60 of 131 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07754331Renal Insufficiency · United States | 1 | Completed | AstraZeneca | Oct 6, 2026 | 10 |
| NCT07662109Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 3 | Recruiting | AstraZeneca | Jul 5, 2028 | 2,000 |
| NCT07662044Diabetes Mellitus, Type 2 · United States, Argentina, China and more | 3 | Recruiting | AstraZeneca | Jul 14, 2028 | 800 |
| NCT07624305Renal Insufficiency, Chronic · United States, Argentina, Austria and more | 3 | Recruiting | AstraZeneca | Jul 1, 2030 | 2,800 |
| NCT07404137Renal Insufficiency, Chronic · United States | 1 | Completed | AstraZeneca | Apr 2, 2026 | 26 |
| NCT07396844Fasting · Thailand | 1 | Completed | LG Chem | Jun 26, 2026 | 28 |
| NCT07399470Healthy Volunteers · South Korea | 1 | Completed | LG Chem | Feb 6, 2026 | 58 |
| NCT07333742Fed Conditions · South Korea | 1 | Completed | LG Chem | Nov 27, 2025 | 50 |
| NCT07222917Renal Insufficiency, Chronic · United States, Argentina, Bulgaria and more | 2 | Active, not recruiting | AstraZeneca | Dec 10, 2026 | 222 |
| NCT07083401Diabetes Mellitus · South Korea | 1 | Recruiting | Boryung Pharmaceutical | Jul 5, 2026 | 40 |
| NCT07083388Diabetes Mellitus · South Korea | 1 | Recruiting | Boryung Pharmaceutical | Jul 3, 2026 | 52 |
| NCT07033585Diabetes Mellitus, Type 2 · United States | 3 | Active, not recruiting | Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair | Oct 18, 2026 | 600 |
| NCT06979388Lecithin Cholesterol Acyltransferase Deficiency · United Kingdom | 1 | Completed | AstraZeneca | Jul 12, 2025 | 14 |
| NCT06942910Kidney Diseases · Russia | 2 | Active, not recruiting | AstraZeneca | Sep 26, 2026 | 224 |
| NCT06742723Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 3 | Recruiting | AstraZeneca | Dec 18, 2029 | 5,000 |
| NCT06677060Heart Failure · United States, Argentina, Australia and more | 3 | Recruiting | AstraZeneca | Dec 17, 2029 | 11,300 |
| NCT06610526Renal Insufficiency, Chronic · China | 4 | Active, not recruiting | AstraZeneca | May 31, 2027 | 731 |
| NCT06268873Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 3 | Active, not recruiting | AstraZeneca | Feb 24, 2028 | 2,554 |
| NCT06269484Liver Cirrhosis · United States, Australia, Belgium and more | 2 | Completed | AstraZeneca | Dec 11, 2024 | 73 |
| NCT06127212Healthy · Indonesia | – | Completed | Dexa Medica Group | Mar 15, 2023 | 24 |
| NCT06087835Kidney Diseases · United States, Argentina, Australia and more | 3 | Active, not recruiting | AstraZeneca | Feb 18, 2027 | 1,835 |
| NCT06063109Hypertension · South Korea | 1 | Completed | thpharm-corp | Nov 9, 2023 | 51 |
| NCT05516498Liver Cirrhosis · United States, Australia, Austria and more | 2 | Terminated | AstraZeneca | May 22, 2025 | 205 |
| NCT05411965Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | Completed | Boryung Pharmaceutical | Jul 3, 2022 | 48 |
| NCT05403281Healthy Subjects · Korea, Republic of | 1 | Completed | dong-wha-pharmaceutical-co-ltd | Dec 3, 2021 | 41 |
| NCT05266404Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus) · Germany | 1 | Completed | AstraZeneca | May 31, 2022 | 46 |
| NCT04991571Renal Insufficiency, Chronic · United States | 1 | Completed | AstraZeneca | Oct 22, 2021 | 27 |
| NCT04899349Breast Neoplasms · United States, Malaysia | 2 | Terminated | Novartis | May 10, 2023 | 2 |
| NCT04881006Healthy Subjects · Canada | 1 | Completed | Hansoh Pharmaceutical Group | Dec 20, 2020 | 30 |
| NCT04880993Healthy Subjects · Canada | 1 | Completed | Hansoh Pharmaceutical Group | Dec 24, 2020 | 30 |
| NCT04856969Healthy Adult Volunteers · Korea, Republic of | 1 | Completed | autotelicbio | May 4, 2021 | 38 |
| NCT04856007Healthy Volunteer · China | 1 | Completed | AstraZeneca | Jun 14, 2021 | 80 |
| NCT04634500Diabetes Mellitus, Type 2 · Korea, Republic of | 3 | Completed | Daewoong Pharmaceutical | Nov 3, 2021 | 200 |
| NCT04620590Diabetes Mellitus, Type 2 · United States, Canada | 4 | Completed | George Clinical Pty | May 30, 2023 | 17 |
| NCT04595370Heart Failure · United States, Belgium, Bulgaria and more | 2 | Completed | AstraZeneca | Sep 22, 2023 | 153 |
| NCT04564742Heart Failure · Sweden, United Kingdom | 3 | Completed | AstraZeneca | Jul 5, 2023 | 4,017 |
| NCT04544319T2DM | 1 | UNKNOWN | LG Chem | Mar 2021 | 44 |
| NCT04445714Diabetes Mellitus, Type 2 · India | 4 | Completed | AstraZeneca | Mar 14, 2023 | 196 |
| NCT04356742Diabetes Mellitus, Type 2 · Korea, Republic of | 3 | Completed | Dong-A ST | Feb 23, 2022 | 198 |
| NCT04255238Diabetes Mellitus, Type 2 | 3 | UNKNOWN | LG Chem | May 30, 2022 | 468 |
| NCT03877237Heart Failure With Reduced Ejection Fraction (HFrEF) · United States, Brazil, Canada and more | 3 | Completed | AstraZeneca | Mar 7, 2020 | 313 |
| NCT03877224Heart Failure With Preserved Ejection Fraction (HFpEF) · United States, Argentina, Brazil and more | 3 | Completed | AstraZeneca | Jul 9, 2020 | 504 |
| NCT03766724Type2 Diabetes · Korea, Republic of | 1 | Completed | Dong-A ST | Jan 18, 2019 | 42 |
| NCT03619213Heart Failure With Preserved Ejection Fraction · United States, Argentina, Belgium and more | 3 | Completed | AstraZeneca | Mar 27, 2022 | 6,263 |
| NCT03658031Prediabetic State · Qatar | 3 | UNKNOWN | Hamad Medical | Dec 31, 2020 | 576 |
| NCT03608358Diabetes Mellitus, Type 2 · Thailand, Vietnam | 3 | Terminated | AstraZeneca | Aug 4, 2020 | 41 |
| NCT03565458Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | UNKNOWN | LG Chem | Aug 20, 2018 | 48 |
| NCT03387683Diabetes Mellitus, Type 2 · Finland, Sweden | 4 | Completed | AstraZeneca | Mar 19, 2019 | 53 |
| NCT03344341Diabetes Mellitus, Type 2 · China | 4 | Terminated | AstraZeneca | May 24, 2019 | 304 |
| NCT03338855Diabetes Mellitus, Type 2 · Netherlands | 4 | Completed | AstraZeneca | Nov 4, 2019 | 26 |
| NCT03199053Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Feb 1, 2023 | 256 |
| NCT03169959Diabetes Mellitus, Type 2 · United States | 1 | Completed | AstraZeneca | Aug 3, 2017 | 85 |
| NCT03138356Diabetes Mellitus, Type 2 · United Kingdom | 1 | Completed | AstraZeneca | Nov 28, 2017 | 126 |
| NCT03152084Diabetes Mellitus, Type 2 · Netherlands, Sweden | 4 | Terminated | AstraZeneca | Mar 20, 2020 | 24 |
| NCT03216278Lecithin Cholesterol Acyltransferase Deficiency · Brazil | 1 | Completed | AstraZeneca | May 22, 2018 | 284 |
| NCT03036150Renal Insufficiency, Chronic · United States, Argentina, Brazil and more | 3 | Completed | AstraZeneca | Jun 12, 2020 | 4,304 |
| NCT03036124Heart Failure · United States, Argentina, Brazil and more | 3 | Completed | AstraZeneca | Jul 17, 2019 | 4,744 |
| NCT02725593Diabetes Mellitus, Type 2 · United States, Hungary, Israel and more | 3 | Completed | AstraZeneca | Apr 6, 2020 | 72 |
| NCT02719132Diabetes Mellitus, Type 2 | 4 | Withdrawn | AstraZeneca | Nov 2017 | 0 |
| NCT02722239Diabetes Mellitus, Type 2 · Russian Federation | 1 | Completed | AstraZeneca | May 5, 2016 | 40 |
How it is read
Names in the registry
- “Dapagliflozin”, 90 entries
- “dapagliflozin”, 18 entries
- “Dapagliflozin 10 mg”, 6 entries
- “Dapagliflozin 10mg”, 5 entries
- “Dapagliflozin/metformin XR 10/1000mg”, 4 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 80 studies
- Renal Insufficiency, Chronic, 8 studies
- Heart Failure, 7 studies
- Diabetes Mellitus, 7 studies
- Diabetes Mellitus, Type 1, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.